Scinai Immunotherapeutics Ltd.’s Post

On this World Atopic Eczema Day, LEO Pharma shines a spotlight on atopic dermatitis (AD) - the most common form of eczema that affects millions of people across the globe. This chronic inflammatory skin condition not only causes physical discomfort with symptoms such as itch and pain, but also impacts the quality of life for patients, their families and caregivers. With AD often persisting into and sometimes beginning in adulthood, the condition results in a lifetime patient burden that is one of the largest among diseases worldwide. At LEO Pharma, we are driven to innovate to address such patient needs and strive to make a fundamental difference for those living with skin conditions. #LEOPharma #DermatologyBeyondTheSkin #AtopicEczemaDay

On this World Atopic Eczema Day, LEO Pharma shines a spotlight on atopic dermatitis (AD) - the most common form of eczema that affects millions of people across the globe. This chronic inflammatory skin condition not only causes physical discomfort with symptoms such as itch and pain, but also impacts the quality of life for patients, their families and caregivers. With AD often persisting into and sometimes beginning in adulthood, the condition results in a lifetime patient burden that is one of the largest among diseases worldwide. At LEO Pharma, we are driven to innovate to address such patient needs and strive to make a fundamental difference for those living with skin conditions. #LEOPharma #DermatologyBeyondTheSkin #AtopicEczemaDay

In recognition of #MelanomaAwarenessMonth, AMLo Biosciences are sharing (to US-only audience) a patient case study demonstrating the clinical utility of their #AMBLor technology that accurately stratifies early-stage, low-risk melanomas. https://lnkd.in/eehgYpVY AMBLor® testing service is provided by Avero Diagnostics as a physician-ordered, laboratory-developed test (LDT). The AMBLor test meets the U.S. Food and Drug Administration (FDA) definition and requirements for LDTs, but it has not been reviewed by the FDA. #dermatology #dermatopathology #histopathology #oncology #skincancer #cancerresearch #biomarkers

On this World Atopic Eczema Day, LEO Pharma shines a spotlight on atopic dermatitis (AD) - the most common form of eczema that affects millions of people across the globe. This chronic inflammatory skin condition not only causes physical discomfort with symptoms such as itch and pain, but also impacts the quality of life for patients, their families and caregivers. With AD often persisting into and sometimes beginning in adulthood, the condition results in a lifetime patient burden that is one of the largest among diseases worldwide. At LEO Pharma, we are driven to innovate to address such patient needs and strive to make a fundamental difference for those living with skin conditions. #LEOPharma #DermatologyBeyondTheSkin #WorldAtopicEczemaDay #AtopicDermatitis

A New Horizon in Melasma Treatment: Photobiomodulation Therapy Photobiomodulation therapy (PBM), a versatile technique in the field of skin disease treatment, is gaining attention. Especially when it comes to treating melasma, a chronic hyperpigmentation condition, PBM is showing significant potential. Recent research suggests that the development of melasma is associated with vascular features and dermal photoaging, posing significant treatment challenges. However, PBM, with its unique approach, offers new possibilities. We conducted a comprehensive review of the literature over the past decade and identified nine relevant studies on PBM for melasma treatment. These studies include clinical trials, in vitro experiments, and animal model research. The results suggest that PBM can effectively reduce the hyperpigmentation associated with melasma. Specific wavelengths (red: 630 nm; amber: 585 and 590 nm; infrared: 830 and 850 nm) at radiant exposures between 1 and 20 J/cm2 can modulate tyrosinase activity, affecting the gene expression and protein synthesis of melanocytic pathway components, thereby significantly reducing melanin content. Additionally, PBM can improve the dermal structure, reduce erythema and neovascularization, which are pathological components of melasma. Therefore, PBM is considered a promising, modern, and non-invasive procedure for treating melasma. Beyond its role in inhibiting melanogenesis, PBM also shows potential in reducing erythema and vascularization and improving dermal conditions. Source: https://bit.ly/3Q8hPgg Contact: ROY | Sales Specialist Mobile/WeChat/WhatsApp: +86 15572700927 Company Website: https://lnkd.in/g7QnTwRh E-mail: dwipayan_roy@kaiyanmedical.com #Photobiomodulation #MelasmaTreatment #SkinCare #Dermatology #Hyperpigmentation #ClinicalTrials #MedicalInnovation #NonInvasiveTherapy #PBM #kaiyanMedical

Check out the NACE Webcast: Atopic Dermatitis: Evaluation and Targeted Management. Atopic dermatitis (AD) is a chronic relapsing and remitting inflammatory skin disease that commonly presents in childhood. It is characterized primarily by scaly, pruritic, erythematous lesions located on flexural surfaces. The itch that accompanies AD has a significant impact on patients’ quality of life, with the most prominent impact being on sleep quality. Fortunately, a new understanding of its underlying pathophysiology has brought about a variety of effective treatment options for patients suffering from AD, from topical agents to biologics and oral Janus kinase (JAK) inhibitors. In this webcast, Mona Shahriari, MD, FAAD, will share her valuable insights on differential diagnosis, treatment goals, and individualizing treatment plans. Click here to start the course: https://bit.ly/3WdObsm #NACE #Dermatology #Webcast

📢 January 2024's British Journal of Dermatology Summaries are now available to view. 📢 The summaries aim to make #dermatology research findings more accessible to those without formal medical training. Below is the link to the summaries that have a particular focus on #psoriasis: ⭐A study looking at a possible new drug, HB0017, for the treatment of psoriasis https://lnkd.in/ePRvgfUM ⭐ A pharmacogenetic study of psoriasis supports the association between a gene (KLK7) and treatment response https://lnkd.in/eQ-Ns2rE ⭐ The role of enhancers in eczema and psoriasis https://lnkd.in/eugN7u36

PEGASUS’ was a randomised double blind placebo controlled #trial of a Bruton Tyrosine Kinase Inhibitor (BTKI) in pemphigus. Rilzabrutinib is a reversible BTKI. In this global study, new onset and recalcitrant pemphigus vulgaris (PV-90%) and foliaceus (PF-10%) patients were treated with medium doses of prednisone (o.5 mg/kg/d) and randomised to rilza vs placebo. The primary outcome was the proportion of PV patients in Complete remission (no lesions- PDAI zero for at least 8 weeks) on minimal therapy at week 37. In this original protocol, p<0.05 but the trial was completed during the pandemic and FDA mandated excluding patients with remote visits and that minimal therapy be increased to 10mg/d pred; with these restrictions, p>0.05. Murrell et al https://lnkd.in/dNg8iNrU #derm #RCT #pemphigus #rilzabrutinib #clinicaltrial #phase3 #outcomes #PDAI #safety #international #dermatology #principiabio #sanofi #BTKI The PEGASUS study was conducted from January 8, 2019 through October 8, 2021, in 19 countries (Argentina, Australia, Brazil, Bulgaria, Canada, Croatia, France, Germany, Greece, Israel, Italy, Poland, Serbia, Spain, Taiwan, Turkey, Ukraine, United Kingdom, and United States).

𝑪𝒀𝑴𝑩𝑰𝑶𝑻𝑰𝑪𝑺 𝑺𝑲𝑰𝑵-𝑯𝑬𝑨𝑳𝑻𝑯 𝑰𝑵𝑺𝑰𝑮𝑯𝑻𝑺 📝 Exploring the Transcriptional Landscape of the Human Sebaceous Gland Sebaceous glands (SGs) play a crucial role in maintaining skin health, but when their function is disrupted, it can lead to skin disorders like acne and affect broader physiological processes. Researchers in this study, offer the first high-resolution map of sebaceous differentiation using advanced spatial transcriptomics, pseudotime analysis, RNA velocity, and functional enrichment methods. Discover how this research unravels the stages of sebocyte differentiation, highlights key gene expression changes, and opens doors to novel therapeutic targets for skin disorders. Dive in to explore the future of sebaceous gland research and its implications for dermatology: https://lnkd.in/gUXDAsDn #Dermatology #Research #SkinResearch #Transcriptomics #SkinHealth #SkinDisorder #Biotechnology #Biopharma #Innovation #Cymbiotics DAYLAN P., Maneesh Paul. S., M. Sc., Ph.D., FIDSA., Rachana B Urs, Manuela Saakshi Maria Schmidt, Florian Hansmann, Henry Löffler-Wirth, Christos C. Prof. Dr. Zouboulis

⚠️Despite the fact that seborrheic keratosis is quite easy to diagnose, there are cases that cause difficulties in diagnosing this disease. 🔶Sometimes the doctor encounters pigmented seborrheic keratosis - therefore, it is necessary to carry out a differential diagnosis with melanoma, pigmented basalioma, actinic keratosis, and melanocytic nevus. 🍀The photo shows a formation on the back skin that looks like a seborrheic keratoma. 🔎After dermatoscopy, a clinical diagnosis was made - melanoacanthoma, a type of seborrheic keratosis. It is a benign formation. 🔬Now, after removal of the mass, the removed material will be sent for histologic examination to confirm the clinical diagnosis. 🤗Remember that early diagnosis is the key to successful treatment and the opportunity to live on and pleasing the loved ones. #longevity #healthyaging #tissuerepair #skinaging #aging #skindiseases #biohacking #treatmentofskindiseases #drandreynovikov #andreynovikov #dermatology #doctornovikov #novikovclinic #amdclinic #dermatologist #dermatooncologist #regenerativemedicine #aestheticmedicine #cosmetology #cosmetologist #skincancer #dermatoscopy #dermoscopy #benignskintumors #nevus #moles #moleremoval #cancerprevention #basalcellcarcinoma #skincheck #skincancerawareness #keratoma